Laronib 25MG & 100MG (Larotrectinib)
Product Name : Laronib
Generic Name : Larotrectinib
Formulation : Capsule
Available Pack Size : 30’s
Available Strengths : 25mg & 100mg
Registrations : Export Only
Product Information
Laronib (Larotrectinib) 25mg and 100mg is a first-in-class, highly selective TRK (tropomyosin receptor kinase) inhibitor used for the treatment of solid tumours that carry an NTRK gene fusion, in adult and paediatric patients, regardless of tumour location or type. It works by selectively inhibiting TRKA, TRKB, and TRKC, the abnormal fusion proteins created when the NTRK1, NTRK2, or NTRK3 genes fuse with an unrelated gene, blocking the oncogenic signalling that drives these genetically-defined cancers. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Laronib (Larotrectinib) 25mg and 100mg
| Brand Name | Laronib (Larotrectinib) |
| Generic Name | Larotrectinib (as Larotrectinib Sulfate) INN |
| Drug Class | Tropomyosin Receptor Kinase (TRK) Inhibitor (TRKA/TRKB/TRKC) |
| Available Strengths | 25mg and 100mg |
| Formulation | Capsule |
| Pack Size | 30 Capsules per Pack (Each Strength) |
| Primary Indication | NTRK Gene Fusion-Positive Solid Tumours (Tumour-Agnostic Indication) |
| Regulatory Approvals | USFDA Approved (Accelerated Approval, Tumour-Agnostic). EMA Approved. |
| Originator Brand | Vitrakvi by Bayer and Loxo Oncology |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Status | Export Only – Manufactured for International Markets |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Laronib (Larotrectinib) Works
Laronib contains Larotrectinib, the first oral TRK inhibitor developed, designed to selectively inhibit TRKA, TRKB, and TRKC, receptor proteins encoded by the NTRK1, NTRK2, and NTRK3 genes. In certain cancers, chromosomal rearrangements cause one of these genes to fuse with an unrelated gene, producing an abnormal TRK fusion protein that is constitutively active and drives uncontrolled tumour cell growth, regardless of where in the body the cancer originates.
Larotrectinib binds to and inhibits these TRK fusion proteins with high potency, blocking the abnormal signalling that drives tumour proliferation and survival. Because TRK fusions can occur across many different cancer types, from salivary gland tumours and soft-tissue sarcoma to thyroid cancer and infantile fibrosarcoma, Laronib is approved as a tumour-agnostic therapy, treating cancers based on their genetic driver rather than the organ in which they originated. Patient selection is based on an FDA-approved diagnostic test confirming NTRK gene fusion status.
Laronib is taken as a twice-daily oral capsule, with or without food, offering a targeted precision-medicine option for adult and paediatric patients whose tumours are driven by this specific genetic alteration.
Indication for Laronib (Larotrectinib)
Laronib (Larotrectinib) is indicated for the following condition:
|
NTRK Gene Fusion-Positive Solid Tumours For adult and paediatric patients with solid tumours that have an NTRK gene fusion without a known acquired resistance mutation, that are metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. Patient selection is based on an FDA-approved test. |
Benefits of Laronib (Larotrectinib) 25mg and 100mg
|
First Tumour-Agnostic TRK Inhibitor Laronib was among the first cancer therapies approved based on a tumour’s genetic driver rather than its location, giving patients with rare NTRK fusion-positive cancers a dedicated targeted option. |
High, Consistent Response Rates Clinical trials of Larotrectinib demonstrated substantial overall response rates across a wide range of NTRK fusion-positive tumour types in both adult and paediatric patients. |
Suitable Across Age Groups Laronib is approved for both adult and paediatric patients, with dosing that can be adjusted by body surface area for younger or smaller patients. |
|
Affordable Alternative to Vitrakvi Laronib contains the same active ingredient as Vitrakvi by Bayer and Loxo Oncology, at a significantly lower cost, making this precision therapy more financially accessible. |
Two Strengths for Flexible Dosing The 25mg and 100mg capsule strengths make it easier to reach the exact prescribed dose, including body-surface-area-based dosing for smaller paediatric patients. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Laronib capsules. |
How to Take Laronib (Larotrectinib)
Route: Oral, taken with a glass of water. Capsules should be swallowed whole.
Standard dose for adults and paediatric patients with body surface area ≥1.0 m²: 100mg orally twice daily, continued until disease progression or unacceptable toxicity, exactly as directed by the prescribing oncologist.
Dose for paediatric patients with body surface area under 1.0 m²: 100mg/m² orally twice daily (maximum 100mg per dose), calculated and prescribed by the treating paediatric oncologist based on body surface area.
With food: Can be taken with or without food.
Missed dose: If a dose is missed, take it as soon as possible unless the next dose is due within 4 hours; do not double up doses.
Dose reduction for toxicity: Treatment may be interrupted and the dose reduced in defined steps to manage adverse reactions such as hepatotoxicity or neurologic symptoms, as directed by the prescribing physician.
Hepatic impairment: The starting dose should be reduced by 50% in patients with moderate or severe hepatic impairment.
CYP3A4 interactions: Avoid coadministration with strong CYP3A4 inhibitors and inducers where possible, as these significantly alter Larotrectinib plasma exposure. Larotrectinib may also increase the plasma concentration of sensitive CYP3A4 substrate medications.
Paediatric use: Laronib is approved for paediatric patients with NTRK fusion-positive solid tumours, dosed by body surface area as directed by a paediatric oncology specialist.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Laronib treatment. Your oncologist will check liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) before starting treatment, every 2 weeks during the first 2 months, then monthly thereafter, or more frequently following any significant liver enzyme elevation. Monitoring also includes regular assessment for neurologic symptoms such as dizziness, difficulty walking, numbness, tingling, or confusion, most of which occur within the first three months of treatment. Report any yellowing of the skin or eyes, dark urine, severe dizziness, difficulty walking, confusion, or mood changes to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Laronib with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, and clarithromycin), as these can significantly increase Larotrectinib exposure, and strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin), as these can significantly reduce Larotrectinib exposure and effectiveness.
Use caution when combining Laronib with sensitive CYP3A4 substrate medications, as Larotrectinib may increase their plasma concentrations. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Laronib.
Side Effects and Precautions
|
Common Side Effects Fatigue Dizziness Nausea and vomiting Cough Constipation Swelling of the ankles, feet, or hands Elevated liver enzymes Muscle pain and low blood cell counts |
Serious Warnings and Precautions Hepatotoxicity, requiring regular liver function monitoring, particularly in the first two months of treatment. Neurologic adverse reactions, including dizziness, gait disturbance, paraesthesia, and cognitive or mood changes. Risk of impaired coordination and alertness. Avoid driving or hazardous activities until effects are known. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Laronib (Larotrectinib)?
Laronib is suitable for adult and paediatric patients with solid tumours confirmed to carry an NTRK gene fusion by an FDA-approved test, whose cancer is metastatic, where surgical resection is likely to cause severe morbidity, or where standard treatments have failed or are unsuitable. It is prescribed by medical and paediatric oncologists experienced in genomically-guided, tumour-agnostic cancer therapy. A thorough medical assessment including NTRK fusion testing, baseline liver function, and neurological assessment is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, hematology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Laronib under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Laronib is one of Everest’s specialty precision-oncology products, offering a bioequivalent alternative to Vitrakvi by Bayer and Loxo Oncology at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Laronib (Larotrectinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Laronib (Larotrectinib) from Mediaid Pharmacy?
Laronib represents one of the most precise forms of cancer therapy available, treating tumours based on their underlying genetic driver rather than their location in the body. As the generic equivalent of Vitrakvi by Bayer and Loxo Oncology, it delivers the same active ingredient, Larotrectinib, with the same proven TRK-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Laronib gives patients and families worldwide access to tumour-agnostic precision therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Larotrectinib option with worldwide delivery, Laronib from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Laronib (Larotrectinib)
What is Laronib (Larotrectinib) used for?
Laronib (Larotrectinib) is used to treat adult and paediatric patients with solid tumours that carry an NTRK gene fusion, regardless of where the cancer originated in the body. It is a tumour-agnostic therapy, meaning treatment eligibility is based on the tumour’s genetic makeup rather than its location, and is used when the cancer is metastatic, hard to resect, or has not responded to other treatments.
How should I take Laronib (Larotrectinib)?
Laronib is taken orally, twice daily, with or without food, with a glass of water. The standard dose is 100mg twice daily for adults and larger paediatric patients. Smaller paediatric patients are dosed based on body surface area. Always follow your oncologist’s exact instructions, as dosing is individualised.
What strengths is Laronib (Larotrectinib) available in?
Laronib is available in 25mg and 100mg capsules, each supplied in a pack of 30 capsules. Having two strengths available makes it easier to reach the exact prescribed dose, particularly for paediatric patients dosed by body surface area.
Is Laronib the same as Vitrakvi (Larotrectinib by Bayer)?
Yes. Laronib is the generic equivalent of Vitrakvi. Both contain the same active ingredient, Larotrectinib, and work through the same TRK-inhibition mechanism. Laronib is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism as Vitrakvi at a significantly lower cost.
What are the side effects of Laronib (Larotrectinib)?
Common side effects include fatigue, dizziness, nausea, cough, constipation, and swelling of the hands or feet. Serious but less common risks include liver injury and neurologic effects such as dizziness, gait disturbance, and confusion, which affected around half of patients in clinical trials. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Can Laronib be used with other medications?
Laronib should not be combined with strong CYP3A4 inhibitors or inducers without a physician-directed dose adjustment, and it may increase the levels of other CYP3A4 substrate medications. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Laronib.
Is Laronib (Larotrectinib) safe during pregnancy or breastfeeding?
No. Laronib is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Laronib (Larotrectinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Laronib (Larotrectinib) 25mg and 100mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Laronib (Larotrectinib) 25mg and 100mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
